A randomized phase II study of anlotinib combined with STUPP versus STUPP alone in patients with newly diagnosed glioblastoma (GBM)

被引：0
|
作者：
Chen, Yuan Yuan Yuan
Dong, Baiqiang
Chen, Zhongping
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Neurosurg Neurooncol, Ctr Canc, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2079
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. A.
    Beal, K.
    Karimi, S.
    Chan, T. A.
    Panageas, K.
    Nayak, L.
    Seko, B.
    DeAngelis, L. M.
    Abrey, L. E.
    Gutin, P. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
    Nayak, Lakshmi
    Molinaro, Annette M.
    Peters, Katherine
    Clarke, Jennifer L.
    Jordan, Justin T.
    de Groot, John
    Nghiemphu, Leia
    Kaley, Thomas
    Colman, Howard
    McCluskey, Christine
    Gaffey, Sarah
    Smith, Timothy R.
    Cote, David J.
    Severgnini, Mariano
    Yearley, Jennifer H.
    Zhao, Qing
    Blumenschein, Wendy M.
    Duda, Dan G.
    Muzikansky, Alona
    Jain, Rakesh K.
    Wen, Patrick Y.
    Reardon, David A.
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 1048 - 1057
  • [43] Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma
    Butowski, N. A.
    Lamborn, K.
    Chang, S.
    Thornton, D.
    DeBoer, R.
    Page, M.
    Rabbitt, J.
    Parvanateni, R.
    Kivett, V.
    Nicol, S.
    Prados, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Hypofractionated accelerated radiotherapy (HART) with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM)
    Mallick, Supriya
    Haresh, K. P.
    Gupta, Subhash
    Sharma, Seema
    Laviraj, M. A.
    Upadhyay, Ashish Dutt
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] TOXICITY OF COMBINED BEVACIZUMAB-LOMUSTINE TREATMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM): REPORT FROM A RANDOMIZED PHASE II STUDY
    van den Bent, Martin
    Taal, Walter
    Sleijfer, Stefan
    van Heuvel, Irene
    SillevisSmitt, Peter A.
    Bromberg, Jacoline E.
    Vernhout, Irene
    NEURO-ONCOLOGY, 2010, 12 : 42 - 42
  • [46] GOG 3088: a randomized phase II study of letrozole versus observation in patients with newly diagnosed uterine leiomyosarcoma
    Corr, Bradley
    Sill, Michael
    Klein, Jennifer
    Herzog, Thomas
    Coleman, Robert
    Slomovitz, Brian
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A347 - A347
  • [47] GOG 3088: A randomized phase II study of letrozole versus observation in patients with newly diagnosed uterine leiomyosarcoma
    Corr, Bradley
    Sill, Michael
    Klein, Jennifer
    Herzog, Thomas J.
    Coleman, Robert L.
    Slomovitz, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM)
    Nabors, L. B.
    Mikkelsen, T.
    Batchelor, T.
    Lesser, G.
    Rosenfeld, M.
    Ye, X.
    Piantadosi, S.
    Olson, J.
    Brem, S.
    Grossman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma -: A phase II study
    Weller, M
    Streffer, J
    Wick, W
    Kortmann, RD
    Heiss, E
    Küker, W
    Meyermann, R
    Dichgans, J
    Bamberg, M
    CANCER, 2001, 91 (02) : 423 - 427
  • [50] Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma
    Wen, PY
    Gigas, DC
    MacDonald, L
    Batchelor, TT
    Schiff, D
    Xu, R
    Ramakrishna, N
    Weaver, S
    Kracher, J
    Bradshaw, J
    Levy, B
    Bailey, E
    Kesari, S
    Maher, EA
    Henson, J
    Black, PM
    NEURO-ONCOLOGY, 2004, 6 (04) : 385 - 385
12345